TABLE 1.
Baseline characteristics of early‐stage ENKTL patients in this study (N = 202)
| Characteristic | Number (%) |
|---|---|
| Age | |
| Median (range) | 44.0 (18–73) |
| ≤60 years | 176 (87.1%) |
| >60 years | 26 (12.9%) |
| Sex | |
| Male | 140 (69.3%) |
| Female | 62 (30.7%) |
| Ann Arbor stage | |
| I | 112(55.4%) |
| II | 90 (44.6%) |
| ECOG‐PS | |
| 0–1 | 188 (93.1%) |
| ≥2 | 14 (6.9%) |
| B symptoms | |
| No | 121 (59.9%) |
| Yes | 81 (40.1%) |
| Extensive primary tumor | |
| No | 89 (44.1%) |
| Yes | 113 (55.9%) |
| Regional lymph node involvement | |
| No | 113 (55.9%) |
| Yes | 89 (44.1%) |
| UADT involvement | |
| No | 7 (3.5%) |
| Yes | 195 (96.5%) |
| Circulating EBV‐DNA | |
| Negative | 67 (33.2%) |
| Positive | 117 (57.9%) |
| Unknown or missing | 18 (8.9%) |
| Elevated LDH | |
| No | 147 (72.8%) |
| Yes | 55 (27.2%) |
| IPI | |
| Low‐risk | 186 (92.1%) |
| Intermediate‐low‐risk | 16 (7.9%) |
| Intermediate‐high‐risk | 0 (0.0%) |
| High‐risk | 0 (0.0%) |
| KPI | |
| Group 1 | 56 (27.7%) |
| Group 2 | 80 (39.6%) |
| Group 3 | 53 (26.2%) |
| Group 4 | 13 (6.4%) |
| PINK | |
| Low‐risk | 170 (84.2%) |
| Intermediate‐risk | 31 (15.3%) |
| High‐risk | 1 (0.5%) |
| PINK‐E | |
| Low‐risk | 162 (80.2%) |
| Intermediate‐risk | 21 (10.4%) |
| High‐risk | 1 (0.5%) |
| Unknown | 18 (8.9%) |
| NRI | |
| Low‐risk | 41 (20.3%) |
| Intermediate‐low‐risk | 75 (37.1%) |
| Intermediate‐high‐risk | 41 (20.3%) |
| High risk | 45 (22.3%) |
Note: Data are shown as number (%) or median (range). The sum of some percentages may not equal 100% because of rounding. EBV, Epstein–Barr virus; ECOG‐PS, Eastern Cooperative Oncology Group performance status; ENKTL, extranodal natural killer/T‐cell lymphoma, nasal‐type; IPI, international prognostic index; KPI, Korean prognostic index; LDH, lactate dehydrogenase; NRI, nomogram‐revised risk index; PINK, prognostic index of natural killer lymphoma; PINK‐E, PINK model with circulating EBV‐DNA; UADT, upper aerodigestive tract.